Skip to main content
. 2009 May 22;9:9. doi: 10.1186/1471-2210-9-9

Table 1.

Hit peptide names, sequences and physical properties

Name Sequence cyclization Buffer Solubility (μM) ALogP % Inhibition of RGS4-Gαo
YJ34 Ac-VKCTGICE-NH2 S-S 80 -2.58 -17 ± 4 (40 μM)

1nd YNCQGECK-NH2 S-S ≥ 420 -2.8 2 ± 4

1ad Ac-YNCQGECK-NH2 S-S 123 -2.37 14 ± 6

2nd GTCFGTCW-NH2 S-S 464 -0.37 19 ± 3**

2ad Ac-GTCFGTCW-NH2 S-S 30 0.08 10 ± 4 (10 μM)

3nd LVCKGYCQ-NH2 S-S ≥ 470 -0.37 12 ± 2

3ad Ac-LVCKGYCQ-NH2 S-S 427 0.17 10 ± 3

4nd KVCMGGCT-NH2 S-S ≥ 470 -2.02 4 ± 3

4ad Ac-KVCMGGCT-NH2 S-S 459 -2.09 9 ± 6

5nl YWCKGLCK-NH2 Linear 465 1.46 -1 ± 10

5al Ac-YWCKGLCK-NH2 Linear 460 1.66 -2 ± 4

5nd* YWCKGLCK-NH2 S-S 463 0.48 80 ± 5***

5ad* Ac-YWCKGLCK-NH2 S-S 464 1.04 37 ± 3***

5nm YWCKGLCK-NH2 S-me-S ≥ 470 0.53 3 ± 0.1 (100 μM)

6nd* KHCYGFCY-NH2 S-S Low 0.94 23 ± 15 (25 μM) *

6ad* Ac-KHCYGFCY-NH2 S-S 421 1.24 27 ± 4***

Solubility in buffer was determined experimentally by HPLC. ALogP calculations are from http://www.vcclab.org, [9]. Percent inhibition values (50 μM unless otherwise stated) are from Figure 1, 2C, or 3A (mean ± S.E.M., n ≥ 3) *p < 0.05, **p < 0.01, ***p < 0.001 compared to no peptide. Peptides with significant inhibition in the FCPIA are in bold. *Peptides 5 and 6 were previously reported as peptides 7 and 14, respectively in Roof et al 2008.